Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia

Authors:
  • WAWing-Yan Au
    Wing-Yan Au
  • CKCyrus R. Kumana
    Cyrus R. Kumana
  • MKMaybelle Kou
    Maybelle Kou
  • RMRaymond Mak
    Raymond Mak
  • CLChing-Wan Lam
    Ching-Wan Lam
  • YKYok-Lam Kwong
    Yok-Lam Kwong

Abstract
Treated with oral As2O3 were 12 consecutive unselected patients with relapsed APL (Table 1). The relapse was confirmed morphologically (> 30% blasts + abnormal promyelocytes in the marrow) and cytogenetically (presence of t(15;17), with none of the cases showing additional karyotyic aberrations) or molecularly (presence of PML/RARA). The treatment was given with informed consent, and the protocol was approved by the institutional review board of the University of Hong Kong. All patients had a pretreatment Karnofsky score higher than 80%. Routine monitoring included alternate daily blood counts and renal/liver function tests (LFTs), and electrocardiography (ECG) daily in the initial week, then weekly.

This publication has 10 references indexed in Scilit: